« Return to News | Drug Sponsors

ITI, Takeda in collaboration

Thursday, March 3, 2011 02:40 PM

Intra-Cellular Therapies has entered into a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia and a variety of psychiatric and neurological diseases, according to FierceBiotech.

ITI has retained the option to co-promote with Takeda in the U.S., and will be eligible for $500 million in development milestones plus another $250 million in sales-based milestones, along with tiered royalty payments.

Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors. ITI's PDE1 inhibitors are orally-available, preclinical-stage compounds.

"We are able to enhance our central nervous system pipeline, one of our core therapeutic areas, through this collaboration," said Shigenori Ohkawa, chief scientific officer for Takeda. “We plan to accelerate our R&D activities for this compound in an effort to bring this novel medicine to patients as quickly as possible."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.